The reason is thought to be that αPD-1 can bind PD-1 on T cells, blocking the binding of PD-1 to both PD-L1 and PD-L2 ligands on antigen-presenting cells (APC; cancer cells) at the same time. Here, PDCD1 is linked to cancer.